Cell biology

BD Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters

Retrieved on: 
Friday, April 5, 2024
Genomics, Flow cytometry, Cell, Drug discovery, Laser, BDX, Cell biology, Research, Science, Workflow, AACR, EMBL, Family

FRANKLIN LAKES, N.J., April 5, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of new cell sorters that will enable more researchers in a broader range of fields, including cell biology, cancer research and immunology, to reveal insights that were previously invisible in traditional flow cytometry experiments.

Key Points: 
  • The new BD FACSDiscover™ S8 Cell Sorters feature BD CellView™ Image Technology, profiled on the cover of the journal Science in 2022, and BD SpectralFX™ Technology — bringing to market breakthrough innovations in real-time imaging and spectral flow cytometry.
  • The three- and four-laser additions to the BD FACSDiscover™ S8 Cell Sorter family complement the five-laser instrument launched last year and provide scientists greater access, options, and flexibility to incorporate real-time imaging and spectral cell sorting technology in their labs.
  • "It has the same sorting speed and software capabilities as the five-laser unit, making experiments extremely scalable on an easy-to-use instrument."
  • The family of BD FACSDiscover™ Cell Sorters will be featured at upcoming conferences beginning with the American Association for Cancer Research (AACR) Annual Meeting, April 5-10, and is now available to order through local sales representatives.

Poets&Quants™ Honors Best & Brightest Business Majors For 2024

Retrieved on: 
Monday, April 1, 2024
University of Virginia, Organization, Dean's list, University of California, Berkeley, Best, National Science Foundation, Business, Business administration, Bloomberg Businessweek, Cornell University, SAN, School, Research, Undergrads, Jordan Fowler, News, Cell biology, Haas School of Business, University, Faculty, Times Higher Education, Student, MBA, Woman, Marketing, Poet, Dyson School, Molecule, Management

SAN FRANCISCO, April 1, 2024 /PRNewswire/ -- Poets&Quants For Undergrads, the leading news source for undergraduate business education, has released its ninth annual "Best & Brightest Business Majors" feature. The story honors 100 of the most accomplished seniors who majored in fields like business administration, marketing, finance, and operations.

Key Points: 
  • SAN FRANCISCO, April 1, 2024 /PRNewswire/ -- Poets&Quants For Undergrads , the leading news source for undergraduate business education, has released its ninth annual "Best & Brightest Business Majors" feature.
  • This year's 100 Best & Brightest feature includes students like Jacob Williams, a McKinsey-bound senior studying at the University of California-Berkeley's Haas School of Business.
  • To compile this year's Best & Brightest students, Poets&Quants reached out to the 50 highest-ranked schools in its 2024 Undergraduate Business School Ranking .
  • To read the Best & Brightest Business Majors of 2024, CLICK HERE .

CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference

Retrieved on: 
Wednesday, March 13, 2024
CRRT, Conference, Pneumonia, CRAC, Disease, Incidence, GFR, AKI, Patient, Physiology, COVID-19, Renal artery, Biomarker, Hemofiltration, T helper 17 cell, Mortality, Indiana University, Cell biology, Glomerular filtration rate, Respiratory failure, Doctor of Philosophy, Acute kidney injury, Ischemia, Kidney, Poster, Stage 2, Blood, Animal, Hospice and palliative medicine, Pharmaceutical industry

LA JOLLA, Calif., March 13, 2024 /PRNewswire/ -- CalciMedica Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, last evening presented data from preclinical studies of Auxora™ in acute kidney injury (AKI) at the 29th International Acute Kidney Injury and Continuous Renal Replacement Therapy Conference (AKI & CRRT) in San Diego, CA. David Basile, Ph.D., Professor of Anatomy, Cell Biology and Physiology at Indiana University, gave an oral and poster presentation entitled "The Store-Operated Calcium Channel Inhibitor Auxora Improves Renal Function Following Ischemia-Induced Acute Kidney Injury in Rats."

Key Points: 
  • In rats with kidney injury akin to Stage 3 AKI, the rats treated with placebo died while those on Auxora survived and showed modest recovery of GFR.
  • We are excited as these studies support clinical observations of Auxora that suggest the drug may be beneficial for AKI patients."
  • The data presented at AKI & CRRT was from a series of studies referred to as Study 1 and Study 2.
  • These results indicate that Auxora has the ability to hasten the recovery of kidney function and improve survival in rat models of AKI.

Bezos Earth Fund Vice Chair Lauren Sánchez Announces $60 Million to Establish Bezos Centers for Sustainable Protein

Retrieved on: 
Tuesday, March 12, 2024
Climate change, Absorption, Farmer, Pressure, Science, Agriculture, Livestock, Cell biology, Climate, Food, Carbon, Biodiversity loss, Methane, Jeff Bezos, Invention, Engineering, Aspen

MIAMI, March 12, 2024 /PRNewswire/ -- Today at Aspen Ideas: Climate , Bezos Earth Fund Vice Chair Lauren Sánchez announced an initial $60 million commitment to establish Bezos Centers for Sustainable Protein as part of the Bezos Earth Fund's $1 billion commitment to food transformation.

Key Points: 
  • MIAMI, March 12, 2024 /PRNewswire/ -- Today at Aspen Ideas: Climate , Bezos Earth Fund Vice Chair Lauren Sánchez announced an initial $60 million commitment to establish Bezos Centers for Sustainable Protein as part of the Bezos Earth Fund's $1 billion commitment to food transformation.
  • The Centers will target major technological barriers to reducing cost, increasing quality, and boosting nutritional benefit of alternative proteins by advancing science and technology.
  • To date, challenges in biomanufacturing—the production, at scale, of sustainable protein products, whether plant-based, fermented, or cultivated—are resulting in high costs and limited quality.
  • This announcement builds on the Bezos Earth Fund's $1 billion commitment to support farmers and expand food production in a sustainable manner.

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Retrieved on: 
Tuesday, March 5, 2024
Axonal transport, Tauopathy, Neuron, CRVO, Cell biology, DLB, Plasma, Medical laboratory, MB, Phosphorylation, Overalls, FTD, GS, Vrije Universiteit Amsterdam, Publication, MAPK, Glial fibrillary acidic protein, GFAP, Axon, Brain, CNR, IW, EM, SDL, UCL, RAF kinase, Alpha-synuclein, Conference, Biomarker, AG, Lewy body, GBA, MD, Neurochemistry, PDF, JC, CP, Patient, Dementia, Basal forebrain, JA, Medical imaging

BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the presentation of biomarker data from the AscenD-LB Phase 2a trial of neflamapimod in patients with dementia with Lewy bodies (DLB), demonstrating that neflamapimod reduces plasma levels of glial fibrillary acidic protein (GFAP) compared placebo, and that the effects of neflamapimod on GFAP were inversely correlated to change in CDR-SB (reduction in GFAP associated with improvement in CDR-SB, and increase in GFAP associated with worsening in CDR-SB). These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024. In addition, academic researchers from UCL will be presenting data in a separate poster at the meeting demonstrating that p38MAPK inhibition, including with neflamapimod specifically, improves tau-induced axonal transport defects both in vitro and in a tauopathy mouse model.

Key Points: 
  • These data will be featured in a poster presentation at the 18th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024, being held both virtually and in Lisbon, Portugal from March 5–9, 2024.
  • “The effects on GFAP, particularly the association between GFAP response and clinical outcomes, further support that neflamapimod is clinically efficacious in patients with DLB,” said John Alam, MD, Chief Executive Officer of CervoMed.
  • A PDF copy of the GFAP poster presentation will be available on the “ Presentations and Publications ” section of the CervoMed website.
  • Title: NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

Wistar Scientists Discover Link Between Leaky Gut and Accelerated Biological Aging

Retrieved on: 
Friday, February 23, 2024
Methylation, Dysbiosis, Culture, Penn Center, Health, Bacteria, University, Subtypes of HIV, Life Length, Wistar Institute, Bangladesh Technical Education Board, Ileum, Infection, NIH, AIDS, Glass, Metabolomics, Nucleotide, DSM-IV codes, Biomedical Research, HIV/AIDS research, Wistar, University of Pittsburgh, DNA, Immune system, National Institutes of Health, Leiden University Medical Center, Weill Cornell Medicine, Hannum, Research, Inflammation, Blood, Ageing, Cancer, Cell biology, Microbiome, Rush University, HIV, DNA methylation, Vaccine

Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.

Key Points: 
  • Dr. Abdel-Mohsen investigates what drives this rapid aging and how to create ways to slow down biological aging and improve health.
  • A prime suspect in this aging puzzle is the gut microbiome and its potential leakage into the bloodstream.
  • The Abdel-Mohsen lab investigates how gut leakage can impact the immune system and lead to chronic inflammation, which may accelerate aging.
  • Their analysis revealed a significant connection between disrupted gut microbiomes, increased intestinal permeability (leaky gut), and faster biological aging.

WhiteSwell Announces Six-month Outcomes After eLym System Treatment for Acute Decompensated Heart Failure Patients in its DELTA-HF Study

Retrieved on: 
Wednesday, March 6, 2024
Medical Devices, Health, Surgery, Clinical Trials, Cardiology, Biotechnology, Peripheral edema, Thoracic duct, Acute decompensated heart failure, Ohio State University, Physiology, Drainage, Congestion, Heart failure, ADHF, Cell biology, Death, Patient, Lymphatic system, Medicine, THT, Tissue, Pharmaceutical industry

WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.

Key Points: 
  • WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart failure (ADHF), announced today positive six-month follow-up data on the initial nine patients treated in its ongoing DELTA-HF trial evaluating the WhiteSwell eLym™ System.
  • Nine hospitalized patients with ADHF received eLym therapy in conjunction with diuretic therapy and were followed for six months.
  • Reduced rehospitalizations: Comparing patients’ clinical course before and after eLym therapy, in the six months prior to eLym therapy there were 13 heart failure related hospitalizations, while in the six months after eLym therapy there were just two heart failure hospitalizations and one heart failure related death, for a 77% reduction.
  • The minimally invasive catheter system was successfully deployed and removed in all patients, with a mean treatment time of 24 hours.

Society for Laboratory Automation and Screening (SLAS) Selects CytoTronics’ Pixel System for 2024 New Product Award

Retrieved on: 
Tuesday, March 5, 2024
Software, Research, Pharmaceutical, Hardware, Biometrics, Apps, Applications, Technology, Semiconductor, Health Technology, Science, Biotechnology, Health, Laboratory automation, Metabolism, Multimedia, Electrophysiology, SLAS, Epithelium, Conference, Society, Cell biology, Exhibition, ISSCR, Television

CytoTronics, Inc. , a pioneer of semiconductor-based platforms for discovery in cell biology, is pleased to announce that their Pixel ™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).

Key Points: 
  • CytoTronics, Inc. , a pioneer of semiconductor-based platforms for discovery in cell biology, is pleased to announce that their Pixel ™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).
  • Award selection was announced at the SLAS2024 International Conference and Exhibition in Boston, MA on February 6th, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240305158077/en/
    CytoTronics' Pixel™ system received the 2024 New Product Award from the Society for Laboratory Automation and Screening (SLAS).
  • Front-runners are interviewed on-site at the conference by a panel of industry veterans with deep expertise in laboratory automation and screening techniques to determine final award recipients.

3D Cell Cultures Technologies Report 2024, Featuring Profiles of Leading Market Participants Including Abcam, Agilent Technologies, Corning, Merck, Beckman Coulter and Synvivo - ResearchAndMarkets.com

Retrieved on: 
Monday, February 26, 2024
Health, Infectious Diseases, Other Science, Research, Pharmaceutical, Science, Agilent Technologies, Collagen, Cancer, Merck, Regenerative medicine, 2D, Abcam, Drug resistance, Gel, Liver disease, Stem cell, 3D, Growth, Drug discovery, Metastasis, Skin, Cell, HCMI, Safety, COVID-19, Cell biology, Patient, Burns, Biology, Software, Corning Inc., 3D printing

3D cell culture technologies are a powerful tool for studying cell biology, disease mechanisms and drug discovery.

Key Points: 
  • 3D cell culture technologies are a powerful tool for studying cell biology, disease mechanisms and drug discovery.
  • 3D cell culture models mimic the 3D structure and cell-cell interactions that are found in real tissues, making them more accurate and predictive than traditional 2D cell culture models.
  • There are a variety of 3D cell culture technologies available, including:
    Scaffold-based 3D cell culture: This approach uses a scaffold to provide a 3D support structure for cells to grow on.
  • Bioprinting: This approach uses a 3D printer to deposit cells and biomaterials layer-by-layer to create complex 3D cell culture models.

Iron Restriction Keeps Blood Stem Cells Young

Retrieved on: 
Friday, March 8, 2024
Bone marrow, Multimedia, Iron, Blood, Inflammation, Albert Einstein, Novartis, HSC, Ageing, Animal, Cell, Risk, B cell, University, Cell biology, Cell Stem Cell, Medicine, DRS, Research, Mouse

BRONX, N.Y., March 8, 2024 /PRNewswire/ -- As we age, our hematopoietic (blood-forming) stem cells (HSCs) become less able to produce new red and white blood cells and other vital blood components—contributing to chronic inflammation and accelerating the onset of blood cancers and degenerative diseases.

Key Points: 
  • BRONX, N.Y., March 8, 2024 /PRNewswire/ -- As we age, our hematopoietic (blood-forming) stem cells (HSCs) become less able to produce new red and white blood cells and other vital blood components—contributing to chronic inflammation and accelerating the onset of blood cancers and degenerative diseases.
  • "So basically, iron restriction governs and protects the regenerative capacity of stem cells—their ability to divide and to differentiate into blood cells," said the paper's co-corresponding author Yun-Ruei Kao, Ph.D. , research assistant professor of oncology and of medicine at Einstein.
  • Compared with controls, aged HSCs exposed to iron chelation produced significantly more blood cells after their HSCs were transplanted into other mice.
  • Dr. Will is currently exploring HSCs and iron from several angles: how to safely limit iron in HSCs during aging; whether restricting iron levels within HSCs can prevent their aging-associated transformation into cancerous HSCs; and to what extent other adult stem cells, such as those in the gut, depend on iron restriction to reliably regenerate tissues and organs.